No Data
No Data
Autolus Therapeutics Presents Longer-term Follow-up and Additional Data Analysis of Pivotal Phase 2 FELIX Study of Obe-cel for Adult R/r B-ALL in an Oral Presentation at ASCO
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes40% patients are in ongoing remission without subsequent stem cell transplant
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading
Tech stocks led European equities traded in the US as American depositary receipts modestly higher Thursday morning, rising 0.4% to 1,428.1 on the S&P Europe Select ADR Index. From continental Europe,
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading
European equities traded in the US as American depositary receipts were trending modestly higher late Tuesday morning, rising 0.32% to 1,431.33 on the S&P Europe Select ADR Index. From continental Eur
Autolus Therapeutics: A Strong Buy on Promising Obe-cel Developments and Strategic Readiness
Buy Rating Affirmed: Autolus Therapeutics' Strategic Position and Upcoming Catalysts Promise Upside Potential
Earnings Call Summary | Autolus Therapeutics(AUTL.US) Q1 2024 Earnings Conference
The following is a summary of the Autolus Therapeutics Plc (AUTL) Q1 2024 Earnings Call Transcript:Financial Performance:Autolus Therapeutics reported a Q1 2024 operating loss of $38.8 million, a slig
No Data